CRISPR Therapeutics’ (CRSP) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a report published on Thursday,Benzinga reports. HC Wainwright currently has a $65.00 target price on the stock.

CRSP has been the topic of a number of other reports. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Barclays upped their price target on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a research report on Wednesday. Truist Financial lifted their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday. Needham & Company LLC restated a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday. Finally, Royal Bank of Canada cut their target price on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $74.05.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $43.49 on Thursday. The stock has a market capitalization of $3.71 billion, a P/E ratio of -15.37 and a beta of 1.67. The business has a 50 day simple moving average of $42.06 and a two-hundred day simple moving average of $46.25. CRISPR Therapeutics has a 12 month low of $36.52 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. As a group, research analysts anticipate that CRISPR Therapeutics will post -5.08 EPS for the current fiscal year.

Insider Activity

In other news, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors have recently modified their holdings of the business. Highline Wealth Partners LLC purchased a new position in CRISPR Therapeutics in the fourth quarter valued at $39,000. Western Pacific Wealth Management LP increased its holdings in CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in CRISPR Therapeutics in the 3rd quarter valued at about $40,000. Darwin Wealth Management LLC purchased a new position in shares of CRISPR Therapeutics in the 3rd quarter valued at about $43,000. Finally, Eastern Bank acquired a new position in shares of CRISPR Therapeutics during the third quarter worth about $70,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.